GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors

NCT00074022 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

Recurrent Non-small Cell Lung Cancer
Recurrent Prostate Cancer
Stage III Prostate Cancer
Stage IIIA Non-small Cell Lung Cancer
Stage IIIB Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Stage IV Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

BIOLOGICAL: GTI-2040
DRUG: docetaxel
OTHER: laboratory biomarker analysis
OTHER: pharmacological study

Sponsor

National Cancer Institute (NCI)